Attovia Therapeutics is down 31% since six insiders disclosed purchases
- Insider
- Goldman Sachs Group Inc
- Company
- Attovia Therapeutics, Inc. (ATTO)
- Transaction
- Buy
- Shares
- 1M
- Amount
- $17M
- Trade date
- Aug 6, 2026
- Filed
- Aug 13, 2026, 7 days after the trade
- Source
- SEC Form 4 ↗
Goldman Sachs Group Inc bought 1M shares of Attovia Therapeutics, Inc. at $17.00 on August 6, 2026, for a total of $17M. The purchase was reported to the SEC on August 13, 2026, 7 days after the trade.
Five other insiders, including Frazier Life Sciences XI, L.P., Redmile Group, LLC and Sanofi, also disclosed purchases between August 5, 2026 and August 6, 2026.
Attovia closed at $13.89 on October 19, 2026, 31.1% below the first close after the purchase ($20.17 on Aug 7, 2026). No sales by Goldman Sachs Group Inc in the company have been reported since.
ATTO −0.5% on the day, close Oct 30
Since purchase−31.1%$20.17 → $13.89
Since filing−30.1%$19.86 on Aug 14 → $13.89
Purchase$17M1M shares on Aug 6, 2026
Days since purchase74No sales by this filer since
Price since the purchase
Daily close · USD0%
−30%
Aug 7 · first close $20.17Oct 19 · $13.89
PurchaseFirst close below −30%